Your browser doesn't support javascript.
loading
Validation of Residual Cancer Burden as Prognostic Factor for Breast Cancer Patients After Neoadjuvant Therapy.
Müller, Hannah Deborah; Posch, Florian; Suppan, Christoph; Bargfrieder, Ute; Gumpoldsberger, Melanie; Hammer, Robert; Hauser, Hubert; Dandachi, Nadia; Prein, Kurt; Stoeger, Herbert; Lax, Sigurd; Balic, Marija.
Afiliación
  • Müller HD; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Posch F; Comprehensive Cancer Center Graz, Medical University of Graz, Graz, Austria.
  • Suppan C; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Bargfrieder U; Comprehensive Cancer Center Graz, Medical University of Graz, Graz, Austria.
  • Gumpoldsberger M; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Hammer R; Comprehensive Cancer Center Graz, Medical University of Graz, Graz, Austria.
  • Hauser H; Department of Pathology, Hospital Graz South-West, Graz, Austria.
  • Dandachi N; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Prein K; Comprehensive Cancer Center Graz, Medical University of Graz, Graz, Austria.
  • Stoeger H; Department of Surgery, Hospital Graz South-West, Graz, Austria.
  • Lax S; Department of Surgery, Hospital Graz South-West, Graz, Austria.
  • Balic M; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Ann Surg Oncol ; 26(13): 4274-4283, 2019 Dec.
Article en En | MEDLINE | ID: mdl-31452052
BACKGROUND: Assessing the residual cancer burden (RCB) predictive performance, the potential subgroup effects, and time-dependent impact on breast cancer patients who underwent neoadjuvant therapy in a developer's independent cohort is essential for its usage in clinical routine. METHODS: Between 2011 and 2016, the RCB scores of 184 female breast cancer patients were prospectively collected, and subsequent clinicopathological and follow-up data were obtained retrospectively. Recurrence-free survival (RFS), overall survival (OS), as well as subgroup analysis, and time-dependent variables were calculated with multivariate, complex, or linear statistical models. RESULTS: A total of 184 patients (HER2 33%, TNBC 27%), with a mean follow-up time of 4 years, treated with neoadjuvant systemic therapy (92% anthracycline-taxane based) were analyzed revealing 43 events (38 recurrences, 28 deaths). High RCB scores were associated with recurrence (median index: 2.34 vs. 1.39 points, rank-sum p < 0.0001), decreased RFS (hazard ratio [HR] = 1.80, 95% confidence interval [CI] 1.44-2.24, p < 0.0001) and reduced OS (HR 1.96, 95% CI 1.49-2.59, p < 0.0001). The RCB score showed proportionality of hazards (interaction HR with linear follow-up time = 1.00, p = 0.896) and good discriminating power (Harrell's c index 0.7). CONCLUSIONS: Our results confirm the RCB score as externally valid prognostic marker and being independent of molecular subtype for RFS and OS in a clinical setting.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasia Residual / Terapia Neoadyuvante / Recurrencia Local de Neoplasia Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Middle aged Idioma: En Revista: Ann Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasia Residual / Terapia Neoadyuvante / Recurrencia Local de Neoplasia Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Middle aged Idioma: En Revista: Ann Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Estados Unidos